Evidence map›Paper›PMID 39511193›Full record

ArticleNature communications2024

Small molecule modulation of protein corona for deep plasma proteome profiling.

Ali Akbar Ashkarran, Hassan Gharibi, Seyed Amirhossein Sadeghi, Seyed Majed Modaresi, Qianyi Wang, Teng-Jui Lin, Ghafar Yerima, Ali Tamadon, Maryam Sayadi, Maryam Jafari and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ali Akbar Ashkarran *Precision Health Program, Michigan State University, East Lansing, MI, USA.
Hassan Gharibi *Division of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-3072-4929
Seyed Amirhossein SadeghiDepartment of Chemistry, Michigan State University, East Lansing, MI, USA.
Seyed Majed ModaresiBiozentrum, University of Basel, Basel, Switzerland.ORCID 0000-0001-9747-9748
Qianyi WangDepartment of Chemistry, Michigan State University, East Lansing, MI, USA.
Teng-Jui LinDepartment of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-4691-1059
Ghafar YerimaMolecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California Berkeley, Berkeley, CA, USA.ORCID 0009-0003-5292-8505
Ali TamadonMolecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California Berkeley, Berkeley, CA, USA.ORCID 0009-0009-8763-3401
Maryam SayadiDepartment of Biomedical Engineering, Michigan State University, East Lansing, MI, USA.
Maryam JafariDivision of ENT Diseases, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Zijin LinPrecision Health Program, Michigan State University, East Lansing, MI, USA.
Danilo RitzProteomics Core Facility, Biozentrum, University of Basel, Basel, Switzerland.
David KakhniashviliProteomics and Metabolomics Core Facility, University of Tennessee Health Science Center, Memphis, TN, USA.
Avirup GuhaCardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Mohammad R K MofradMolecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California Berkeley, Berkeley, CA, USA.ORCID 0000-0001-7004-4859
Liangliang SunDepartment of Chemistry, Michigan State University, East Lansing, MI, USA.ORCID 0000-0001-8939-5042
Markita P LandryDepartment of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-5832-8522
Amir Ata SaeiDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. amir.saei@ki.se.ORCID 0000-0002-2639-6328
Morteza MahmoudiPrecision Health Program, Michigan State University, East Lansing, MI, USA. mahmou22@msu.edu.ORCID 0000-0002-2575-9684

Funding

A Nanostructured Skin Patch to Heal Chronic WoundsR01DK131417 · NIDDK · MICHIGAN STATE UNIVERSITY · PI Morteza Mahmoudi · 2022 to 2026
$2.0M
Quantitative top-down proteomics of human colorectal cancer cells and tumorsR01CA247863 · NCI · MICHIGAN STATE UNIVERSITY · PI HUMMON, AMANDA B., LIU, XIAOWEN · 2021 to 2025
$1.9M
NCI NIH HHS R01 CA247863NIDDK NIH HHS R01 DK131417U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) DK131417
6 · The paper itself

Abstract

The protein corona formed on nanoparticles (NPs) has potential as a valuable diagnostic tool for improving plasma proteome coverage. Here, we show that spiking small molecules, including metabolites, lipids, vitamins, and nutrients into plasma can induce diverse protein corona patterns on otherwise identical NPs, significantly enhancing the depth of plasma proteome profiling. The protein coronas on polystyrene NPs when exposed to plasma treated with an array of small molecules allows for the detection of 1793 proteins marking an 8.25-fold increase in the number of quantified proteins compared to plasma alone (218 proteins) and a 2.63-fold increase relative to the untreated protein corona (681 proteins). Furthermore, we discovered that adding 1000 µg/ml phosphatidylcholine could singularly enable the detection of 897 proteins. At this specific concentration, phosphatidylcholine selectively depletes the four most abundant plasma proteins, including albumin, thus reducing the dynamic range of plasma proteome and enabling the detection of proteins with lower abundance. Employing an optimized data-independent acquisition approach, the inclusion of phosphatidylcholine leads to the detection of 1436 proteins in a single plasma sample. Our molecular dynamics results reveal that phosphatidylcholine interacts with albumin via hydrophobic interactions, H-bonds, and water bridges. The addition of phosphatidylcholine also enables the detection of 337 additional proteoforms compared to untreated protein corona using a top-down proteomics approach. Given the critical role of plasma proteomics in biomarker discovery and disease monitoring, we anticipate the widespread adoption of this methodology for the identification and clinical translation of biomarkers.

Indexed as

Blood ProteinsNanoparticlesProtein CoronaProteomeProteomicsHumansHydrophobic and Hydrophilic InteractionsMolecular Dynamics SimulationPhosphatidylcholinesPlasmaPolystyrenesBlood ProteinsPhosphatidylcholinesPolystyrenesProtein CoronaProteome

Identifiers

PMID39511193
PMCPMC11544298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.